Published in J Immunol on December 01, 1979
The inhibitory effects of mycobacterial lipoarabinomannan and polysaccharides upon polyclonal and monoclonal human T cell proliferation. Clin Exp Immunol (1988) 1.75
Leprosy. Clin Microbiol Rev (1988) 1.74
Chemical basis of rough and smooth variation in mycobacteria. J Bacteriol (1989) 1.68
Suppression of lymphocyte responses by tuberculous plasma and mycobacterial arabinogalactan. Monocyte dependence and indomethacin reversibility. J Clin Invest (1981) 1.36
Suppression of T-cell proliferation by Mycobacterium leprae and its products: the role of lipopolysaccharide. Proc Natl Acad Sci U S A (1990) 1.18
Sex differences and estrogen modulation of the cellular immune response after injury. Cell Immunol (2008) 1.16
Variation in interferon-gamma responses to Coxiella burnetii antigens with lymphocytes from vaccinated or naturally infected subjects. Clin Exp Immunol (1993) 1.16
Suppression of cellular immunity to Listeria monocytogenes by activated macrophages: mediation by prostaglandins. Infect Immun (1985) 1.12
Effective vaccination of mice against leprosy bacilli with subunits of Mycobacterium leprae. Infect Immun (1990) 1.04
Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Clin Exp Immunol (1992) 0.98
Suppression of in vitro lymphocyte DNA synthesis by killed Pseudomonas aeruginosa. Infect Immun (1983) 0.95
Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads. Infect Immun (1994) 0.95
Inhibition of interleukin-2 by a Gram-positive bacterium, Streptococcus mutans. Immunology (1998) 0.88
Prostaglandin-dependent regulation of the in vitro proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal donors and from patients with tuberculosis or leprosy. Clin Exp Immunol (1981) 0.88
Suppression of lymphocyte proliferation by Pseudomonas aeruginosa: mediation by Pseudomonas-activated suppressor monocytes. Infect Immun (1985) 0.87
Regulation of human B cell activation by prostaglandin E2. Suppression of the generation of immunoglobulin-secreting cells. J Clin Invest (1985) 0.86
Bacterial lipopolysaccharide-induced immunoglobulin synthesis by human blood lymphocytes partially depleted of monocytes. Clin Exp Immunol (1982) 0.86
Immunosuppressive factor from Actinobacillus actinomycetemcomitans down regulates cytokine production. Infect Immun (1996) 0.86
Deleterious effect of ultraviolet-B radiation on accessory function of human blood adherent mononuclear cells. Clin Exp Immunol (1987) 0.84
Down regulation of macrophage activation in Brugia pahangi-infected jirds (Meriones unguiculatus). Infect Immun (1998) 0.80
Effects of essential fatty acid deficiency on prostaglandin E2 production and cell-mediated immunity in a mouse model of leprosy. Infect Immun (1997) 0.80
Spontaneous cytotoxicity of human peripheral blood mononuclear cells for the lymphoblastoid cell line CCRF-CEM: augmentation by bacterial lipopolysaccharide. Clin Exp Immunol (1981) 0.79
A novel factor isolated from Actinobacillus actinomycetemcomitans stimulates mouse B cells and human peripheral blood mononuclear cells. Infect Immun (2000) 0.77
Release of a suppressor cell-inducing factor by monocytes from patients with pulmonary tuberculosis. Immunology (1991) 0.75
Reversal of lipopolysaccharide-analog-induced antibody suppression by anti-transforming growth factor beta and indomethacin. Infect Immun (1995) 0.75
Monocytes modulate enhancement of HIV-1 replication by Mycobacterium tuberculosis. Clin Exp Immunol (1998) 0.75
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med (1997) 8.43
Inhibition of granulocyte adherence by ethanol, prednisone, and aspirin, measured with an assay system. N Engl J Med (1974) 3.39
Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am J Epidemiol (2003) 3.09
Suppressor adherent cells in human tuberculosis. J Immunol (1978) 2.68
Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol (1989) 2.63
Complement receptor-mediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J Immunol (1994) 2.52
Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot. Proc Natl Acad Sci U S A (1990) 2.46
Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin Infect Dis (1993) 2.39
Human immune response to Mycobacterium tuberculosis antigens. Infect Immun (1991) 2.39
Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS (2000) 2.32
Bidirectional effects of cytokines on the growth of Mycobacterium avium within human monocytes. J Immunol (1991) 2.29
Enhanced production of TGF-beta by blood monocytes from patients with active tuberculosis and presence of TGF-beta in tuberculous granulomatous lung lesions. J Immunol (1995) 2.21
Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immun (1988) 2.21
Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci U S A (1996) 2.15
Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis. J Infect Dis (1993) 2.14
Infective endocarditis caused by slow-growing, fastidious, Gram-negative bacteria. Medicine (Baltimore) (1979) 2.09
Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis (1999) 2.06
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. J Immunol (1986) 2.05
Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (1999) 1.94
Defective interleukin 2 production and responsiveness in human pulmonary tuberculosis. J Exp Med (1986) 1.88
Immunosuppression by mycobacterial arabinomannan. Clin Exp Immunol (1979) 1.87
The effect of bacille Calmette-Guérin vaccination at birth on tuberculin skin test reactivity in Ugandan children. Int J Tuberc Lung Dis (1999) 1.76
Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1. J Infect Dis (1994) 1.76
Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. Clin Exp Immunol (1996) 1.76
A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.74
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS (2001) 1.73
Mycobacterium africanum subtype II is associated with two distinct genotypes and is a major cause of human tuberculosis in Kampala, Uganda. J Clin Microbiol (2002) 1.72
Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med (1999) 1.67
Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol (2001) 1.67
A whole blood bactericidal assay for tuberculosis. J Infect Dis (2001) 1.65
Selective expansion of human gamma delta T cells by monocytes infected with live Mycobacterium tuberculosis. J Clin Invest (1991) 1.60
In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta. Proc Natl Acad Sci U S A (1997) 1.53
Induction of transforming growth factor beta 1 by purified protein derivative of Mycobacterium tuberculosis. Infect Immun (1995) 1.52
Pathogenicity of Mycobacterium avium for human monocytes: absence of macrophage-activating factor activity of gamma interferon. Infect Immun (1989) 1.52
Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis (2000) 1.51
Thromboxane A2 mediates augmented polymorphonuclear leukocyte adhesiveness. J Clin Invest (1980) 1.48
Phytohemagglutinin-induced proliferation of guinea pig thymus-derived lymphocytes. I. Accessory cell dependence. J Immunol (1976) 1.45
Cytokines and tuberculosis. J Leukoc Biol (1994) 1.45
Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis (1999) 1.44
Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis (2001) 1.43
Risk factors for HIV infection in homosexual men: the Cleveland men's study of risks in a low-prevalence area. Cleve Clin J Med (1992) 1.41
Mapping of T cell epitopes of the 30-kDa alpha antigen of Mycobacterium bovis strain bacillus Calmette-Guérin in purified protein derivative (PPD)-positive individuals. J Immunol (1995) 1.40
Selective induction of transforming growth factor beta in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis. Infect Immun (1996) 1.39
Delayed tuberculin reactivity in persons of Indochinese origin: implications for preventive therapy. Ann Intern Med (1996) 1.39
Suppression of lymphocyte responses by tuberculous plasma and mycobacterial arabinogalactan. Monocyte dependence and indomethacin reversibility. J Clin Invest (1981) 1.36
Increased interleukin-1 production and monocyte suppressor cell activity associated with human tuberculosis. Am Rev Respir Dis (1986) 1.35
Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment. J Infect Dis (1998) 1.33
Evidence for activation of a respiratory burst in the interaction of human neutrophils with Mycobacterium tuberculosis. Infect Immun (1987) 1.31
Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr (2001) 1.29
Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis (1997) 1.29
Pleural fluid and peripheral blood lymphocyte function in tuberculosis. Ann Intern Med (1978) 1.28
Non-specific suppression of antigen-induced lymphocyte blastogenesis in Onchocerca volvulus infection in man. Clin Exp Immunol (1983) 1.28
Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother (2001) 1.27
Haemophilus influenzae meningitis: the spectrum of disease in adults. Medicine (Baltimore) (1982) 1.27
Clostridial pleuropulmonary infection. Chest (1980) 1.26
Role of the mononuclear phagocyte as an antigen-presenting cell for human gamma delta T cells activated by live Mycobacterium tuberculosis. Infect Immun (1992) 1.26
Antigen handling by guinea pig macrophages: further evidence for the sequestration of antigen relevant for activation of primed T lymphocytes. J Immunol (1977) 1.25
Chronic meningitis. Medicine (Baltimore) (1976) 1.25
Expression of functional interleukin 2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis. J Clin Invest (1990) 1.24
Anti-Mycobacterium avium activity of quinolones: in vitro activities. Antimicrob Agents Chemother (1993) 1.23
Cell-mediated immune responses in human infection with Onchocerca volvulus. J Immunol (1988) 1.22
The role of TGF beta in the pathogenesis of human tuberculosis. Clin Immunol Immunopathol (1998) 1.21
Pulmonary mononuclear cell responses to antigens of Mycobacterium tuberculosis in healthy household contacts of patients with active tuberculosis and healthy controls from the community. J Immunol (2000) 1.20
A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. Antimicrob Agents Chemother (1994) 1.19
The influence of human immunodeficiency virus infection on tuberculosis in Kampala, Uganda. Am Rev Respir Dis (1991) 1.17
Strain- and donor-related differences in the interaction of Mycobacterium avium with human monocytes and its modulation by interferon-gamma. J Infect Dis (1990) 1.17
Interaction of Mycobacterium tuberculosis-induced transforming growth factor beta1 and interleukin-10. Infect Immun (1999) 1.17
Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis (1998) 1.16
Association of altered dynamics of monocyte surface expression of human leukocyte antigen DR with immunosuppression in tuberculosis. J Infect Dis (1984) 1.16
Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med (2000) 1.15
Spectrum of immunoregulatory functions and properties of human alveolar macrophages. Am Rev Respir Dis (1987) 1.13
Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. Tuber Lung Dis (1997) 1.13
Antigen responsiveness during tuberculosis: regulatory interactions of T cell subpopulations and adherent cells. J Lab Clin Med (1987) 1.12
Role of arginase in killing of schistosomula of Schistosoma mansoni. J Exp Med (1980) 1.12
Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis (1996) 1.12
Immunobiology and species distribution of Mycobacterium tuberculosis antigen 5. Infect Immun (1979) 1.10
Esophageal tuberculosis: mimicry of gastrointestinal malignancy. Rev Infect Dis (1987) 1.09
Evidence against a role for interleukin-10 in the regulation of growth of Mycobacterium avium in human monocytes. J Infect Dis (1996) 1.08
Dyscoordinate expression of tumor necrosis factor-alpha by human blood monocytes and alveolar macrophages. Am Rev Respir Dis (1989) 1.08
Identification of antigens of Mycobacterium tuberculosis using human monoclonal antibodies. J Clin Invest (1989) 1.08
Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients. Clin Diagn Lab Immunol (1995) 1.08
Killing of schistosomula of Schistosoma mansoni by normal human monocytes. J Immunol (1979) 1.06
Amphotericin B-induced resistance to Schistosoma mansoni. J Immunol (1981) 1.05
Phytohemagglutinin-induced proliferation of guinea pig thymus-derived lymphocytes. II. Accessory cell function. J Immunol (1976) 1.04
Defective accessory function of monocytes in human immunodeficiency virus-related disease syndromes. J Lab Clin Med (1988) 1.04
Intrauterine device-associated actinomycosis simulating pelvic malignancy. Am J Gastroenterol (1981) 1.04
Corynebacterium JK: a cause of nosocomial device-related infection. Rev Infect Dis (1986) 1.02
Augmentation of selective monocyte functions in tuberculosis. J Infect Dis (1981) 1.01
Regulation of nuclear factor-kappa B and its inhibitor I kappa B-alpha/MAD-3 in monocytes by Mycobacterium tuberculosis and during human tuberculosis. J Immunol (1997) 1.00
Macrophages, mycobacteria and HIV: the role of cytokines in determining mycobacterial virulence and regulating viral replication. Res Microbiol (1992) 1.00
PPD-specific IgG1 antibody subclass upregulate tumour necrosis factor expression in PPD-stimulated monocytes: possible link with disease pathogenesis in tuberculosis. Clin Exp Immunol (2000) 0.99
Requirement for cell-to-cell contact for the immunosuppressive activity of human alveolar macrophages. Am J Respir Cell Mol Biol (1991) 0.99
Mechanisms of anergy in tuberculosis. Curr Top Microbiol Immunol (1996) 0.99
Pulmonary tuberculosis in a BCG vaccinated area: relationship of disease severity with immunological and hematological parameters and drug resistance patterns. Southeast Asian J Trop Med Public Health (1996) 0.99